Drug Discovery for Neurodegeneration

描述(由申请人提供)：阿尔茨海默氏症药物发现基金会(ADDF)请求U13合作协议拨款，以支持其定于2011年2月6-8日在加利福尼亚州圣地亚哥举行的神经变性药物发现大会。该申请是对奖助金编号的竞争性续签：3U13AG031125-03S1。会议的目的是通过培训下一代科学领导者将基础研究转化为新的疗法来推动神经退行性疾病的药物发现。关于这一主题的正规教育是必要的，因为在这一研究领域存在着有据可查的知识差距，制药行业以外了解这些过程的机会很少。这次教学会议的目标显然与NIH的路线图一致：弥合药物发现和神经退行性疾病方面的知识差距；将跨学科科学家聚集在一起，以激发结合技能和学科的新方法；为这些科学家提供交流思想和资源的网络机会；并最终在科学期刊上发表会议记录。这次会议将向与会者提供有关创造治疗和预防神经退行性疾病的新药的基本知识和资源。它将解决与下列子主题相关的障碍和挑战：药物化学基础；药物发现的早期阶段；临床前概念验证和开发；分子/药物类别；案例研究；技术转让中的问题：相互作用和知识产权；以及推进药物发现的资源和服务。讨论将包括阿尔茨海默病、帕金森氏病、肌萎缩侧索硬化症和多发性硬化症的相关例子。课程将由3至5个演讲组成，并有充足的问答和网络交流时间。由年轻调查人员提供的海报会议也被融入到节目中。关于路线图的公私伙伴关系倡议，亚洲发展基金将邀请来自学术界、工业界和美国国立卫生研究院的27名国际公认的科学家担任主席或发言者。预计这次会议将为150名来自不同背景的科学家服务，其中包括妇女、少数族裔、年轻/初级研究人员和研究生。 公共卫生相关性：ADDF寻求解决的公共卫生问题是减少神经退行性疾病的发病率，如阿尔茨海默病、帕金森氏病、肌萎缩侧索硬化症和多发性硬化症。通过举办这次会议，ADDF将增加科学家对药物发现过程的了解，并促进他们共同努力，开发商业上可行和有效的疾病修改疗法。

DESCRIPTION (provided by applicant): The Alzheimer's Drug Discovery Foundation (ADDF) requests a U13 Cooperative Agreement grant in support of its Drug Discovery for Neurodegeneration conference, scheduled for February 6-8, 2011 in San Diego, CA. The application is a competitive renewal of grant number: 3U13AG031125-03S1. The purpose of the meeting is to advance drug discovery for neurodegenerative disease by training the next generation of scientific leaders on the process of translating basic research into novel therapeutics. Formal education on this topic is needed because there is a documented knowledge gap in this area of research and there are very few opportunities outside of the pharmaceutical industry to learn about these processes. The goals of this didactic conference are clearly consistent with the NIH's Roadmap: to bridge the knowledge gap in drug discovery and neurodegenerative disease; to bring together interdisciplinary scientists to stimulate new ways of combining skills and disciplines; to provide networking opportunities for these scientists to exchange ideas and resources; and to ultimately publish the proceedings in a scientific journal. This conference will give participants fundamental knowledge and resources on creating new drugs to treat and prevent neurodegenerative disease. It will address the barriers and challenges associated with the following sub-topics: Basics of Medicinal Chemistry; Early Phases of Drug Discovery; Preclinical Proof-of-Concept & Development; Molecules/Drug Classes; Case Studies; Issues in Technology Transfer: Interactions & Intellectual Property; and Resources and Services for Advancing Drug Discovery. Relevant examples for Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis will be included in the discussions. Sessions will consist of 3 to 5 presentations with ample time for Q&A and networking. Poster sessions presented by young investigators are also integrated into the program. With respect to the public-private partnership initiative of the Roadmap, the ADDF will invite 27 internationally recognized scientists from academia, industry and NIH to serve as chairs or speakers. It is anticipated that this conference will serve 150 scientists from diverse backgrounds, including women, minorities, young/junior investigators and graduate students. PUBLIC HEALTH RELEVANCE: Relevance The public health problem ADDF seeks to solve is to reduce the incidence of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis. By offering this conference, ADDF will increase scientists' knowledge of the drug discovery processes and catalyze them to work together to develop commercially viable and effective disease modifying therapies.